Targeting the proteins of pathogenic invaders has been a staple strategy when combating infectious disease.  Inevitably, however, the pathogens develop resistance to these treatments and the subsequent rise in drug resistance has sparked numbers calls for new treatment options and strategies.  Some infectious agents, however, exploit native host proteins, raising the possibility of host-orientated treatment options.  Our project focuses on the inhibition of Cathepsin B, a human protease found in lysosomes that is exploited by both Anthax and Ebola.  It is our hope that the development of a potent inhibitor of Cathepsin B will lead to a new host-based treatment option against these deadly infectious agents.

Synthesis of cathepsin B inhibitors as a treatment targeting anthrax and ebola

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.